Correction Issued on MLKL's Role in Liver Aging and Mitochondrial Decline

Cellular senescence and mitochondrial dysfunction in the liver are two of the most intensively studied mechanisms underlying biological aging. As the liver ages, accumulating senescent hepatocytes impair metabolic processing, amplify systemic inflammation, and contribute to age-related diseases including non-alcoholic fatty liver disease and reduced drug metabolism. Understanding what drives hepatic senescence at the molecular level is therefore a priority for longevity researchers.

The original July 2026 paper in Aging Cell put forward a provocative hypothesis: that MLKL — a protein canonically known as the executioner of necroptosis, a form of inflammatory cell death — plays an additional, non-canonical role in hepatocytes. Specifically, the authors proposed that MLKL promotes mitochondrial dysfunction and cellular senescence in the aging liver through a pathway distinct from its cell-killing function. This would implicate MLKL as a dual-function driver of liver aging, making it a potential therapeutic target.

The present entry is a published correction to that original article. The correction notice (DOI: 10.1111/acel.70746) is an erratum referencing the July 2026 publication. No authors are listed in the correction abstract, and no specific details of the amendments are provided in the available text. The nature and extent of the corrections — whether they concern data, figures, statistical analyses, or text — cannot be determined from the abstract alone.

For readers tracking MLKL biology, hepatic senescence, or mitochondrial aging pathways, the practical implication is straightforward: the corrected version of the original paper should be consulted before citing or building upon its findings. Research built on preliminary or uncorrected data risks downstream errors in hypothesis generation or therapeutic development.

The importance of the underlying science is undiminished. MLKL as a senescence-promoting factor in the liver represents a meaningful conceptual advance if validated, and future experimental confirmation of this non-canonical role could open new avenues for senolytic or anti-fibrotic interventions targeting aged hepatocytes.